Comparison of Tagrisso (Osimertinib) with Other EGFR Inhibitors in EGFR-Mutated NSCLC Treatment
Why is EGFR important in cancer patients? EGFR mutations are genetic alterations in the epidermal growth factor receptor (EGFR) gene that lead to uncontrolled cell growth and division. These mutations are found in approximately 10-15% of non-small cell lung cancer (NSCLC) cases, especially among non-smokers and those of Asian descent. Targeted therapies are designed to specifically attack cancer cells with certain mutations, like EGFR while sparing healthy cells. This precision approach leads to better outcomes and fewer side effects compared to traditional chemotherapy. Why EGFR-Mutated NSCLC Requires Specific Treatment? EGFR mutations make NSCLC particularly aggressive and resistant to conventional treatments. Targeted therapies that inhibit the EGFR pathway are crucial in controlling disease progression and improving survival rates. How does osimertinib inhibit EGFR? Third-Generation EGFR Inhibitor: Tagrisso (Osimertinib) is a third-generation EGFR inhibitor specifically desi...